Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
NCT05760586 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2024-08-12
Summary
The DAY101-EAP is a multicenter, open-label, expanded access treatment protocol designed to provide access to tovorafenib (DAY101) for eligible patients.
Conditions
- Low-grade Glioma
Interventions
- DRUG
-
Tovorafenib
Oral RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL)
Sponsors & Collaborators
-
Day One Biopharmaceuticals, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 6 Months
- Max Age
- 25 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)
NCT00704054 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors
NCT05608148 ·Status: RECRUITING ·Phase: PHASE1
-
Topotecan Episcleral Plaque for Treatment of Retinoblastoma
NCT04428879 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors
NCT00024661 ·Status: COMPLETED ·Phase: PHASE1
-
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
NCT01288573 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Topotecan Episcleral Plaque for Treatment of Retinoblastoma
NCT04156347 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma
NCT01466855 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
NCT03618381 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
NCT01445080 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
NCT05734066 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
NCT03015844 ·Status: AVAILABLE
-
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
NCT01431547 ·Status: COMPLETED ·Phase: PHASE1
-
A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.
NCT00560144 ·Status: COMPLETED ·Phase: PHASE1
-
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
NCT01683149 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies
NCT00024648 ·Status: COMPLETED ·Phase: PHASE1
-
Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma
NCT00095186 ·Status: COMPLETED ·Phase: PHASE2
-
Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor
NCT07331064 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients.
NCT02006225 ·Status: UNKNOWN ·Phase: PHASE4
-
Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients
NCT02473497 ·Status: NO_LONGER_AVAILABLE
-
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
NCT01125800 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
NCT02655237 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1
NCT00106158 ·Status: COMPLETED ·Phase: PHASE1
-
Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma
NCT03811886 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
SF1126 for Patients With Relapsed or Refractory Neuroblastoma
NCT02337309 ·Status: TERMINATED ·Phase: PHASE1